Independent directory · not a healthcare provider, pharmacy or seller Directory last updated 2026-07-28
PeptideCare Finder
Clinician-supervised care · not a healthcare provider

Clinician-supervised care · not a healthcare provider

Medical care
Find ClinicsPeptide TherapyFDA StatusCostsMedical Guides
Research suppliers — separate section
Supplier ReviewsCompare SuppliersCOA GuideTesting StandardsRegulatory Actions
GLP-1 receptor agonists · Approved

Tirzepatide: The First Drug Ever Approved for Sleep Apnoea

The first and only drug FDA has approved to treat obstructive sleep apnoea — and FDA’s own statement says the benefit is likely from weight loss, not a direct effect on the airway.

Compiled by the PeptideCare Finder editorial team · Published 2026-08-05 · Updated 2026-07-28 · Not independently reviewed by a clinician
Regulatory and anti-doping status
FDA-approved use
Yes. Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnoea in adults with obesity (December 2024). Mounjaro for type 2 diabetes. Initial approval 2022. Eli Lilly.
Classification here
Approved
Compounding status
FDA declared the tirzepatide shortage resolved in December 2024, ending the basis for widespread compounded supply. FDA proposed in May 2026 not to include it on the 503B Bulks List, finding no clinical need for outsourcing facilities to compound it.
Anti-doping status
Not prohibited. Tirzepatide appears nowhere on the WADA 2026 Prohibited List; it was added to the separate Monitoring Program for 2026.

Every line above is re-verified against the primary agency source before each update. What the July 2026 FDA vote did and did not do →

What tirzepatide is

Tirzepatide is a single engineered peptide that activates two gut-hormone receptors at once, GIP and GLP-1. Both pathways reduce appetite and food intake and improve glucose-dependent insulin secretion. It is given weekly by injection.

What the weight trials showed

SURMOUNT-1 randomised 2,539 adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. Mean weight change ranged from −15.0% to −20.9% across dose arms against −3.1% on placebo.

The sleep-apnoea approval, and how to read it

Two randomised placebo-controlled studies enrolled 469 adults with moderate-to-severe obstructive sleep apnoea and obesity over 52 weeks — one arm in people using positive airway pressure, one in people unable or unwilling to use it. Both showed a significant reduction in the apnoea-hypopnoea index, and FDA approved the indication. FDA also stated that the improvement is likely related to body-weight reduction. That matters: the drug was studied as a treatment for the condition, not validated as a replacement for CPAP.

What the label warns about

Tirzepatide carries the same class boxed warning: in rats it causes dose-dependent thyroid C-cell tumours at clinically relevant exposures, and FDA states the human relevance has not been determined. Contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Warnings cover severe gastrointestinal reactions, kidney injury, gallbladder disease, pancreatitis and aspiration under anaesthesia.

How far up the evidence hierarchy this reaches

An FDA-approved label across three indications, each resting on its own randomised programme. This is the top of the hierarchy.

FDA-approved label This substance reaches here
Adverse reactions observed in trials of known size, in a defined population.
Registered human trials
Useful — but read the size. A few dozen participants cannot detect an uncommon harm.
Animal and in-vitro work
Where the literature for most marketed peptides actually sits. Not evidence of human benefit.
Testimonials and forums
Not evidence. Systematically under-reports harm.
Where a substance's best available evidence sits matters more than any claim made about it.

Where it sits on the compounding pathway

01
Nominated
Someone proposes the substance for compounding use.
02
Category 2
FDA flags significant safety risks pending evaluation.
03
Nomination withdrawn
The nominator pulls it. FDA still publishes its risk language.
04
Advisory committee
A non-binding recommendation. Not a decision.
05 Here
On the 503A Bulks List
The only stage that confers authority. Reached by rulemaking.
As of August 2026 no peptide has reached stage 05. Coverage routinely reports stage 04 as though it were stage 05.

What it is sold for, against what the evidence shows

Marketing claims on the left, in the terms sellers use. What the human literature actually supports on the right.

Marketed forWhat the evidence showsVerdict
Large weight reduction SURMOUNT-1, 2,539 participants, 72 weeks: up to −20.9% against −3.1% on placebo. Supported
Treating obstructive sleep apnoea Two randomised trials, 469 participants, 52 weeks. Approved indication. Supported
Blood-sugar control in type 2 diabetes Approved on the SURPASS phase 3 programme. Supported
"Better than semaglutide" The approved indications rest on placebo-controlled trials, not on a comparative superiority indication. The claim outruns the label. Partly supported
Replacing CPAP Trials enrolled both CPAP users and non-users; benefit tracked weight loss. It was not validated as a substitute. Partly supported
Athletic or body-composition enhancement Not prohibited by WADA, and no performance indication or trial. No human evidence

Where to go next

GLP-1 receptor agonists
Semaglutide
The single-receptor comparison, and the one with a cardiovascular outcomes trial behind it.
GLP-1 receptor agonists
Retatrutide
The three-receptor investigational successor — larger reported weight loss, no approval, and explicitly barred from compounding.
What this guide deliberately omits

No dosing, cycling, stacking, reconstitution or administration instructions appear anywhere on this site, and this page links to no page selling an unapproved injectable. Questions about how a substance would be used belong with a licensed clinician who has evaluated you.

Sources

  1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med, 2022
  2. Malhotra A et al. Tirzepatide for Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med, 2024
  3. DailyMed — ZEPBOUND (tirzepatide), full prescribing information
  4. FDA — FDA Approves First Medication for Obstructive Sleep Apnea, 20 December 2024